Following her training in Paris, France, Dr. Moulin was recruited in 1998 to better understand the complex process of healing. Since 1998, she has been a professor at the Laval University School of Medicine, Department of Surgery, but also a researcher at the LOEX Center at Laval University, and at the Research Center of the CHU de Quebec. Her work focuses on the normal and pathological mechanisms of skin healing. To perform this, she uses different cell culture models reconstituted by tissue engineering to reproduce in vitro fibrotic skin diseases (hypertrophic scars, scleroderma). Concurrently, she also uses the tissue engineering method to reconstruct cutaneous substitutes to treat skin deficient patients, for example, after burns.

Myofibroblasts in normal or pathological scars
These cells appear during wound healing and play an important role in the contraction of the edges of the wound. Dr. Moulin’s team has shown that these cells also play a central role in the production of extracellular matrix, as well as in angiogenesis. They also have a role in the formation of disabling scars such as hypertrophic scars. Dr. Moulin’s team analyzes the different functions of myofibroblasts in normal or pathological scarring; investigates existing interactions between endothelial cells, keratinocytes, fibroblasts and myofibroblasts, and analyzes the role of extracellular matrix secreted by cells in various cellular functions such as apoptosis, angiogenesis or cell differentiation.

Systemic scleroderma
This pathology is a fibrotic disease that stiffens all organs, including the skin, and is eventually fatal. Dr. Moulin uses a tissue-engineering method to understand this pathology, but especially to determine new treatments to reduce fibrosis.

Clinical application of tissue engineering
Tissue engineering skin production is carried out from patients’ cells and then grafted onto them to allow wound closure in patients who are unable to heal after extensive burns or other pathologies. The properties of skin reconstructed by our method are being evaluated in a clinical trial accepted by Health Canada to cover burn victims.

65 entries « 7 of 7 »

Auger FA, Rouabhia M, Goulet F, Berthod F, Moulin V, Germain L

Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: clinical and fundamental applications

Journal Article

Med Biol Eng Comput, 36 (6), 1998.

Abstract | Links:

Laplante AF, Moulin V, Auger FA, Landry J, Li H, Morrow G, Tanguay RM, Germain L

Expression of heat shock proteins in mouse skin during wound healing

Journal Article

J Histochem Cytochem, 46 (11), 1998.

Abstract | Links:

Moulin V, Castilloux G, Auger FA, Garrel D, O'Connor-McCourt MD, Germain L

Modulated response to cytokines of human wound healing myofibroblasts compared to dermal fibroblasts

Journal Article

Exp Cell Res, 238 (1), 1998.

Abstract | Links:

Moulin V, Auger FA, O'Connor-McCourt M, Germain L

Fetal and postnatal sera differentially modulate human dermal fibroblast phenotypic and functional features in vitro

Journal Article

J Cell Physiol, 171 (1), 1997.

Abstract | Links:

Moulin V, Castilloux G, Jean A, Garrel DR, Auger FA, Germain L

In vitro models to study wound healing fibroblasts

Journal Article

Burns, 22 (5), 1996.

Abstract | Links:

65 entries « 7 of 7 »
Signaler des ajouts ou des modifications

Active projects

  • Action des microvésicules dans les tissus solides, from 2019-04-01 to 2025-03-31
  • Allogeneic dermis to accelerate the production of a tissue-engineered skin substitute to treat Canadian burn patients, from 2023-04-01 to 2025-01-31
  • Combining tissue-engineered skin with ex vivo gene therapy correction to develop a treatment for epidermolysis bullosa, from 2022-04-01 to 2024-03-31
  • Cryo-TEM infrastructure for the visualisation of nanoparticles, exosomes and virus-like particles, from 2023-04-01 to 2024-03-31
  • Mise au point par génie tissulaire d'un modèle de cicatrisation cutanée contenant des cellules immunitaires, from 2019-01-27 to 2024-02-29
  • Setting up the conditions for the biobanking of tissues and cells from hypertrophic scars, from 2022-12-01 to 2023-11-30
  • The implication of PlGF in cutaneous fibrosis, from 2022-10-01 to 2027-09-30
  • Tissue engineering to treat Canadian burn patients: the Self-Assembled Skin Substitutes (SASS), from 2022-04-01 to 2025-03-31

Recently finished projects

  • Bioengineering and Long-term Storage of Complex Tissue and Organ Constructs, from 2020-03-31 to 2023-03-30
  • Centre du génie tissulaire (CHU de Québec - Université Laval), from 2019-04-01 to 2023-03-31
  • La réponse immunitaire aux peaux reconstruites avec des cellules allogéniques., from 2022-04-01 to 2023-03-31
  • Self-Assembly Skin Substitutes (SASS) for the treatment of acute wounds of Canadian burn patients, from 2020-01-01 to 2023-01-31
  • The Canadian National Transplant Research Program : Increasing Donation and Improving Transplantation Outcomes, from 2013-04-01 to 2022-03-31
  • The implication of PlGF in cutaneous fibrosis, from 2022-03-01 to 2023-02-28
  • Utilisation de vésicules extracellulaires pour livrer les composants de la technologie d’édition du génome CRISPR/PRIME, from 2021-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery